**Directors' Report and** 

**Unaudited Financial Statements** 

for the Year Ended 31 December 2020

Company Number: 01073169

THURSDAY



A27 30/09/2021
COMPANIES HOUSE

#242

# Contents of the Financial Statements for the year ended 31 December 2020

	Page
Company Information	1
Directors' Report	2
Balance Sheet and Income Statement	3
Notes to the Financial Statements	4

# Company Information for the year ended 31 December 2020

Directors:

B Deluard

P E Parry

E Schmidt

Registered office:

Bampton Road Harold Hill Romford

Essex RM3 8UG

Registered number:

01073169

## Directors' Report for the year ended 31 December 2020

The directors present their report with the financial statements of the company for the year ended 31 December 2020.

### **Directors**

The directors who have held office during the period from 1 Jan	uary 2020 to the date of this report are as follows
---	---

B Deluard

P E Parry

E Schmidt

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

On behalf of the board:

P E Parry - Director

Date: 27/9/2021

## MARTINDALE PHARMACEUTICALS LIMITED (REGISTERED NUMBER: 02581060)

#### Balance Sheet 31 December 2020

	Notes	2020 £	2019 £
Total assets less current liabilities	3		
Capital and reserves Called up share capital Retained earnings	<b>3</b>	100 (100)	100 (100)
Shareholders' funds		<del></del>	<u>-</u>

The company is entitled to exemption from audit under section 480 or the Companies Act 2006 for the year ended 31 December 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2020 in accordance with section 476 of the Companies Act 2006.

The directors acknowledge:

- a) Ensuring the company keeps accounting records which company with Sections 386 and 387 of the Companies Act
- b) Preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and its profit of loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to the financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board of Directors and were signed on its behalf by:

P E Parry - Director

Date: 27/9/2021

# Income Statement For the year ended 31 December 2020

During the financial year and the preceding financial year, the company has not traded and has received no income and incurred no expenditure. Consequently, during those periods the company has made neither a surplus nor a deficit.

## Notes to the Financial Statements for the year ended 31 December 2020

### 1. Statutory information

Martindale Pharmaceuticals Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

### 2. Accounting policies

### Basis of preparing the financial statements

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

### 3. Called up share capital

### Allotted, called up and fully paid

	2020 £	2019 £
100 ordinary shares of £1 each	<u>100</u>	<u>100</u>

### 4. Ultimate controlling party.

The ultimate parent undertaking is Financière Verdi III, a company incorporated in France.

Financière Verdi III prepares group financial statements and copies can be obtained from:

Financière Verdi III 194, Bureaux de la Colline 92213 Saint-Cloud – FRANCE

### 5. Contingent liabilities

The Company has guaranteed bank and other borrowings of a parent undertaking, Orphea Limited, amounting to £55 million (2019: £55 million).